MARKET WIREMoomoo • 18h ago
Citius Oncology (CTOR) Stock Forum and DiscussionMoomoo report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
Why CTOR Stock surged +4.63% Today — RQD Quant Desk Flash
$0.55 +4.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.55
Citius Oncology Inc. (CTOR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $51.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CTOR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CTOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Citius Oncology Inc. (NASDAQ: CTOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.55 (+4.63% 1D, market cap $51.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTOR ranks #644 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CTOR compare to CNTB and HRTX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTOR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTB (Connect Biopharma Holdings Limited) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $50.5M) and HRTX (Heron Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $52.7M). Among the 5-stock peer group, CTOR leads on earnings multiple (N/A) while CTOR leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CTOR?
▼
Per CTOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001851484), Citius Oncology Inc. generated $0 in revenue, -$24.8M in net income, and -$5.5M in free cash flow against $110.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.55 (+0.64%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTOR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY CTOR SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.79-15.2% Next Q
42
Q2 (-2Q)Grade E$0.67-9% Next Q
39
Q3 (-1Q)Grade E$0.61-9.8% Next Q
37
CurrentGrade E$0.55-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CTOR Turnaround Squeeze
While CTOR currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.58) forces dealer call-delta covering toward $1.92.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTOR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CTOR Stock surged +4.63% Today — RQD Quant Desk Flash
Citius Oncology Inc. (CTOR) surged +4.63% to $0.55, trading at 4% of its 52-week range ($0.49 – $1.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($0.49 – $1.83) with RSI-14 at 31 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.55 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CTOR Headlines & Catalysts
MARKET WIRESimply Wall St • 21h ago
Citius Oncology (Nasdaq:CTOR) - Stock AnalysisSimply Wall St report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Citius Oncology Gets Nasdaq Extension to Meet $1 Bid Price RequirementTradingView report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
54 institutions have ordered LYMPHIR, a cancer drug, up from 44 as of Aug. 14.Stock Titan report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Nasdaq gives Citius Oncology (NASDAQ: CTOR) more time to meet its $1 share-price rule.Stock Titan report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Citius (CTOR) Up +5.96% — Is There More Room to Run? 2026-10-21 - Negative Gammahttps://www.siam.in/ report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
CATALYSTStock Titan • 1d ago
With its sales team nationwide, Citius Oncology (CTOR) reports preliminary, unaudited shipment growth.Stock Titan report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHChartMill • 7d ago
After-Hours Movers: SNTI, BRAI, CLS Rise; SPRC, DVLT FallAfter-hours movers: SNTI +54.25%, BRAI +29.25%, CLS +17.17%, SPRC -26.67%, DVLT -22.44% and ONCO -21.70%; CLS, JBLU, WHR and others reported results.
CATALYSTYahoo • 7d ago
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), tod
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTOR)
- ✓Walkthrough of CTOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CTOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.22%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.53H $0.55L $0.53C $0.55VOL 292.8K
RES: $1.34SUP: $0.49SMA50: $0.83SMA200: $0.83
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CTOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CTOR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CTOR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTOR)
Health Care Rank #644 of 1016
⚔️ CNTB vs CTOR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CTOR vs. CNTB, HRTX, XLO, PLRX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Citius Oncology Inc. (CTOR) ranks #644 by composite RQD confidence (34/100, grade E) and #741 by equity capitalization ($51.5M). Within this direct 5-issuer industry benchmark cohort, CTOR leads on earnings valuation at N/A trailing P/E, while CTOR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CTOR currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTOR
ACTIVE
Citius Oncology Inc. | E | 34/100 | — | — | -35.0% | +4.63% | $51.5M | Benchmark Subject |
| CNTB Connect Biopharma Holdings Limited | E | 26/100 | — | — | -35.0% | -3.97% | $50.5M | /cntb-vs-ctor → |
| HRTX Heron Therapeutics Inc. | E | 34/100 | — | 73.3% | -35.0% | -5.67% | $52.7M | /hrtx-vs-ctor → |
| XLO Xilio Therapeutics Inc. | E | 25/100 | — | — | -35.0% | +3.35% | $52.8M | /xlo-vs-ctor → |
| PLRX Pliant Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -0.13% | $53.2M | /plrx-vs-ctor → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001851484In its most recent audited fiscal period (FY2025, filed 2025-09-30), Citius Oncology Inc. (CTOR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$24.8M, operating cash flow of -$5.5M, and free cash flow of -$5.5M (-4446.6% YoY). On the balance sheet, CTOR closed FY2025 with $110.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $0 | -$24.8M | -$5.5M | -$5.5M | $110.0M | — |
| FY2024 (FY) | 2024-09-30 | $0 | -$21.1M | $126.4K | $126.4K | $90.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $2.4M | -$601.3K | -$601.3K | — | — |
3. CTOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CTOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Citius Oncology Inc. (NASDAQ: CTOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.55 (+4.63% 1D, market cap $51.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTOR ranks #644 in composite RQD confidence.
How does CTOR compare to CNTB and HRTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTOR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTB (Connect Biopharma Holdings Limited) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $50.5M) and HRTX (Heron Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $52.7M). Among the 5-stock peer group, CTOR leads on earnings multiple (N/A) while CTOR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CTOR?
Per CTOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001851484), Citius Oncology Inc. generated $0 in revenue, -$24.8M in net income, and -$5.5M in free cash flow against $110.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CTOR trading relative to its 50-day, 200-day, and 52-week technical levels?
CTOR last traded at $0.55 (+4.63% on volume of 292,794 shares), positioning the stock -33.73% below its 50-day simple moving average ($0.83) and -33.73% below its 200-day simple moving average ($0.83). Across its 52-week range of $0.49 to $1.83, CTOR sits at the 4.5% percentile with a 14-day RSI of 31.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.62).
CTOR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CTOR stock moving today?
Why CTOR Stock surged +4.63% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CTOR — Citius Oncology Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:46:57Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CTOR scores 34 out of 100, earning an E grade and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -11.16%. Per the market data, these figures indicate the business is consuming capital rather than generating it, which weakens the case for intrinsic value support at the current price.
- Whale 13F Flow: 8 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score is below midpoint, indicating limited institutional conviction in the source data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this is the weakest pillar, reflecting SEC Form 4 and Congressional PTR cluster flow. A score of 3 indicates little insider-side confirmation of the thesis.
- Macro Regime Fit: 6 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. The score suggests the stock has no clear macro tailwind in the source data.
- Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The Piotroski reading is weak, and the balance sheet provides only partial comfort.
For a prospective investor evaluating the stock today, the composite picture is weak across nearly every pillar. Upside drivers are not evident in the source data, since cash generation, insider flow, and macro fit all score low. Valuation tradeoffs are difficult to assess because earnings-based multiples are unavailable, and the negative ROIC and FCF yield suggest the market is pricing a business that does not yet earn its cost of capital. The brief is educational and does not constitute personalized advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-23.5M | $-24.8M | N/A | $-5.5M | $7.3M | N/A |
| FY 2024 | $0.0M | $-20.6M | $-21.1M | N/A | $0.1M | N/A | N/A |
| FY 2023 | $0.0M | $-1.0M | $2.4M | N/A | $-0.6M | N/A | N/A |
Per the SEC financials, the company reported no revenue across the three periods, with operating losses of $-23.5M in FY 2025 and $-20.6M in FY 2024. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Per the same rating, Debt/Equity is 0.5, but the SEC financials do not report debt figures for the listed periods.
Recent Catalysts & News Wire Analysis
Per the recent news section, the feed contains six items, all tagged to CTOR and all flagged YELLOW under the MARKET WIRE impact label:
- Moomoo and Simply Wall St coverage: general market, institutional, and fundamental commentary with no specific details provided.
- TradingView: reports a Nasdaq extension to meet the $1 bid price requirement, a key listing-compliance risk watch item.
- Stock Titan (two items): reports that 54 institutions have ordered LYMPHIR, up from 44 as of Aug. 14, and separately reports Nasdaq granting more time to meet the $1 share-price rule.
- Benzinga: lists CTOR among Health Care stocks moving in after-market trading, without stated cause.
Risk watch items include the Nasdaq bid-price compliance issue and the price trading below $1 at $0.53. The LYMPHIR order-count item is the only reported commercial indicator in the source data. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. An investor should watch for any future disclosures on manufacturing, licensing, or distribution partners, as the absence of mapped links means ripple effects from suppliers or customers are not assessable here.
Open Questions
- What commercial product, if any, underlies the LYMPHIR institutional order count, and what revenue does it generate?
- What is the status and timeline of the Nasdaq bid-price extension, and what happens if the stock does not regain compliance?
- What is the company's cash runway given $7.3M in cash against a FY 2025 FCF of $-5.5M?
- Why does the company profile show $0.0B market cap while market data shows $49.2M?
- What is the debt position, since the Debt/Equity ratio is reported but no debt figures appear in the financials?
CTOR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Citius Oncology Inc. (CTOR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 18h ago
Citius Oncology (CTOR) Stock Forum and Discussion Moomoo report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 21h ago
Citius Oncology (Nasdaq:CTOR) - Stock Analysis Simply Wall St report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Citius Oncology Gets Nasdaq Extension to Meet $1 Bid Price Requirement TradingView report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
54 institutions have ordered LYMPHIR, a cancer drug, up from 44 as of Aug. 14. Stock Titan report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Monday's After-Market Session Benzinga report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Nasdaq gives Citius Oncology (NASDAQ: CTOR) more time to meet its $1 share-price rule. Stock Titan report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Citius (CTOR) Up +5.96% — Is There More Room to Run? 2026-10-21 - Negative Gamma https://www.siam.in/ report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 1d ago
With its sales team nationwide, Citius Oncology (CTOR) reports preliminary, unaudited shipment growth. Stock Titan report covering Citius Oncology Inc. (CTOR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CTOR Bull vs. Bear Conversation Board — What's Your Call at $0.55?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTOR 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.47 (-11.3%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CTOR (E • RQD 34/100) a Buy at $0.53?
Welcome to the CTOR (Citius Oncology Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.41 (-22.6%)
Spot @ $0.53 Pump the brakes on CTOR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CTOR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Citius Oncology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $0.61 (+15.1%)
Spot @ $0.53 CTOR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CTOR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.53 (52-wk range $0.49 - $1.83), any beat on forward guidance forces shorts and underweight funds to chase.